- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Stellar Biotechnologies, Inc. is pleased to announce that eminent biochemist, Malcolm Gefter, Ph. D. has accepted appointment to both Stellar's Board of Directors and to its Scientific Advisory Board (SAB).
Stellar's CEO, Frank Oakes, said, "The addition of Malcolm Gefter brings great senior-level directive talent and experience to our corporate board in the form of a public biotechnology company CEO, who successfully developed a cutting-edge drug discovery platform and led his company from start-up to acquisition by a major pharmaceutical company. His generous offer of time and energy will also contribute significantly to our Scientific Advisory Board. Stellar gains the insight and wisdom of a true luminary in pharmaceutical product development and commercialization, as well as from his expertise in the technical, regulatory, corporate development and partnership areas. We feel Dr. Gefter completes our initial leadership team."
Dr. Gefter is Professor of Biochemistry Emeritus at MIT. With 275 peer reviewed articles and professorships at both Columbia and MIT, his academic credentials are well established. More recently, he focused his expertise in business and pharmaceutical development, leading Praecis Pharmaceuticals as its CEO from 1989 - 2007. Dr. Gefter received his B.S. in Chemistry from University of Maryland and Ph. D. from Albert Einstein College of Medicine in Molecular Biology. He did postdoctoral work at MRC Laboratory of Molecular Biology in Genetics and Molecular Biology with Brenner and Crick and at the Pasteur Institute under Jacob.
Dr. Gefter said, "Stellar has the key ingredients for success and has a key product in KLH that can reach exceptional revenue and profit targets in both the therapeutic and diagnostic markets with right combination of factors. I look forward to working closely with Executive VP, Dan Morse and SAB Chairman, Andy Saxon as well as the Board of Directors and our science and research vice presidents to help guide Stellar to the kind of success that our shareholders continue to support."
Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
About Stellar Biotechnologies
(OTC: SBOTF - TSX-V: KLH): Stellarís product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety in humans that is used in conjugate therapeutic vaccines and other biomedical products. A world leader in the production of KLH, Stellar plans to further monetize its KLH platform and maximize the impact of its IP portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the rare keyhole limpet, and Stellar has technology for the maintenance of that sea mollusc, and a non-lethal extraction method of the critical molecule that it currently sells into growing academic, research and pharmaceutical markets.
For more information, please click here
Business Development & Finance
Copyright © Stellar BiotechnologiesIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016